Eli Lilly announced that its experimental combination of eloralintide and tirzepatide produced greater weight loss (23.3%) than tirzepatide alone (14.8%) in a Phase 2 trial for obesity and Type 2 diabetes patients. The combo therapy met primary endpoints and plans to advance to Phase 3 trials, though discontinuation rates due to gastrointestinal side effects were higher in the combination group.